Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4

Antiviral Therapy

Volumn 20, Issue 1, 2015, Pages 81-85

  McCormick, Adele L ^a   Wang, Lawrence ^a,b   Garcia Diaz, Ana ^a   Macartney, Malcolm J ^a   Webster, Daniel P ^a   Haque, Tanzina ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b HAVERFORD COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DACLATASVIR; LEUCINE; SERINE; VIRUS RNA; ANTIVIRUS AGENT; BMS-790052; CODON; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CODON; CONTROLLED STUDY; DIAGNOSTIC KIT; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN POLYMORPHISM; DRUG EFFECTS; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MUTATION RATE; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; VIROLOGY;

ANTIVIRAL AGENTS; CODON; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MUTATION RATE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, RNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84926668125     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2763     Document Type: Article

References (18)

1. Belda O, Targett-Adams P. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res 2012; 170:1-14.
2. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013; 3:1-7.
3. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus non-structural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54:1924-1935.
4. Lawitz EJ, Gruener D, Hill JM, et al. A Phase 1, randomized placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 57:24-31.
5. Gao M, Nettles R, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
6. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54:3641-3650.
7. Lok AS, Gardiner D F, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366:216-224.
8. Avá AP, Água-Doce I, Andrade A, Pádua E. Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay. J Med Virol 2013; 85:815-822.
9. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013; 59:375-382.
10. Sun JH, O'Boyle DR, II, Zhang Y, et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus non-structural protein 5A replication complex inhibitor, BMS-79005. Hepatology 2012; 55:1692-1699.
11. Mayers DL, Vince B, Hill JM, et al. IDX719, HCV NS5A inhibitor, demonstrates pan-genotypic activity after three days of monotherapy in genotype 1, 2, 3 or 4 HCV-infected subject. Hepatology 2012; 56:1020A.
12. Hernandez D, Zhou N, Ueland J, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 2013; 57:13-18.
13. Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. in vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 2013; 57:611-613.
14. Wang C, Lingling L, Huang H, et al. in vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother 2012; 56:1588-1590.
15. Plaza Z, Soriano V, Vispo E, et al. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther 2012; 17:921-926.
16. Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012; 54:352-354.
17. Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58:646-654.
18. Max Planck Institut Informatik. geno2pheno. (Accessed 30 September 2013.) Available from www.geno2pheno.org